The CEO of Mylan, which has come under fire for drastically raising the price of its EpiPen, says it's "not true" the company reaps huge profits off its lifesaving allergy treatment.
That's according to testimony Heather Bresch is set to present at a hearing on Wednesday before the House Oversight Committee. Its top members said last week they are sympathetic to the "justified outrage" of families and schools struggling to afford the device.
Also read: Carlos Ghosn Resigns as Nissan CEO
11:44 Morning Agenda: Uber’s Tough Week, Tech Acrimony and Manufacturing6
21:36 White House chief digital officer among six staffers booted last week over FBI background checks: report13
18:17 SodaStream recalls bottles for explosion risk15
17:07 Gonzaga, Villanova, Kansas stay 1-2-3 in AP poll13